[18F]RP-115 PET/MRI for Alzheimer Disease
Phase-Based Progress Estimates
Effectiveness
Safety
China Basin, UCSF, San Francisco, CA
Alzheimer Disease
[18F]RP-115 PET/MRI - DrugEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
This is a first in human study that will assess the safety and diagnostic performance of [18F]RP-115 (fluorine-18 labeled RP115), a positron emission tomography (PET) agent. This agent has the potential to identify the early changes that occur in the brains of patients with Alzheimer disease.
Treatment Effectiveness
Effectiveness Progress
Study Objectives
3 Primary · 1 Secondary · Reporting Duration: A year
A year
Biodistribution of [18F]RP-115
Dosimetry of [18F]RP-115
Safety of Administered dose
Three years
[18F]RP-115 diagnostic performance
Trial Safety
Safety Progress
Trial Design
3 Treatment Groups
Cohort 1 - dosimetry of [18F]RP-115 in healthy volunteers
1 of 3
Cohort 2 - [18F]RP-115 in patients with Alzheimer disease
1 of 3
Cohort 2 - [18F]RP-115 in age-matched controls
1 of 3
Experimental Treatment
68 Total Participants · 3 Treatment Groups
Primary Treatment: [18F]RP-115 PET/MRI · No Placebo Group · Phase < 1
Cohort 1 - dosimetry of [18F]RP-115 in healthy volunteers
Drug
Experimental Group · 1 Intervention: [18F]RP-115 PET/MRI · Intervention Types: DrugCohort 2 - [18F]RP-115 in patients with Alzheimer disease
Drug
Experimental Group · 1 Intervention: [18F]RP-115 PET/MRI · Intervention Types: DrugCohort 2 - [18F]RP-115 in age-matched controls
Drug
Experimental Group · 1 Intervention: [18F]RP-115 PET/MRI · Intervention Types: DrugTrial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: a year
Closest Location: China Basin, UCSF · San Francisco, CA
N/AFirst Recorded Clinical Trial
1 TrialsResearching Alzheimer Disease
0 CompletedClinical Trials
Who is running the clinical trial?
Rio pharmaceuticals Inc.UNKNOWN
David WilsonLead Sponsor
David Wilson, MD, PhDPrincipal InvestigatorUniversity of California, San Francisco
Eligibility Criteria
Age 18+ · All Participants · 9 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You are able to provide written informed consent
You have a suitable artery for catheterization.
You are not a smoker, and you are not taking over the counter nicotine cessation.
You are not taking any central nervous system prescription drugs for three weeks.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
References
- Boche, Delphine, on behalf of the MINC Faculty, Alexander Gerhard, and Elena Rodriguez-Vieitez. 2019. “Prospects and Challenges of Imaging Neuroinflammation Beyond TSPO in Alzheimer’s Disease”. European Journal of Nuclear Medicine and Molecular Imaging. Springer Science and Business Media LLC. doi:10.1007/s00259-019-04462-w.
- Rice, Louise, and Sotirios Bisdas. 2017. “The Diagnostic Value of FDG and Amyloid PET in Alzheimer’s Disease—a Systematic Review”. European Journal of Radiology. Elsevier BV. doi:10.1016/j.ejrad.2017.07.014.
- LI, SHI, MARGARET MALLORY, MICHAEL ALFORD, SEIGO TANAKA, and ELIEZER MASLIAH. 1997. “Glutamate Transporter Alterations in Alzheimer Disease Are Possibly Associated with Abnormal APP Expression”. Journal of Neuropathology and Experimental Neurology. Oxford University Press (OUP). doi:10.1097/00005072-199708000-00008.
- Cowburn, Richard, John Hardy, Peter Roberts, and Roger Briggs. 1988. “Presynaptic and Postsynaptic Glutamatergic Function in Alzheimer's Disease”. Neuroscience Letters. Elsevier BV. doi:10.1016/0304-3940(88)90192-9.
- Jack, Clifford R., Jr., David A. Bennett, Kaj Blennow, Maria C. Carrillo, Billy Dunn, Samantha Budd Haeberlein, David M. Holtzman, et al.. 2018. “NIA‐AA Research Framework: Toward a Biological Definition of Alzheimer's Disease”. Alzheimer's & Dementia. Wiley. doi:10.1016/j.jalz.2018.02.018.
- Innis, Robert B, Vincent J Cunningham, Jacques Delforge, Masahiro Fujita, Albert Gjedde, Roger N Gunn, James Holden, et al.. 2007. “Consensus Nomenclature for in Vivo Imaging of Reversibly Binding Radioligands”. Journal of Cerebral Blood Flow & Metabolism. SAGE Publications. doi:10.1038/sj.jcbfm.9600493.
- Scott, Heather L., Anthony E. G. Tannenberg, and Peter R. Dodd. 2002. “Variant Forms of Neuronal Glutamate Transporter Sites in Alzheimer's Disease Cerebral Cortex”. Journal of Neurochemistry. Wiley. doi:10.1046/j.1471-4159.1995.64052193.x.
- Hoshi, A., A. Tsunoda, T. Yamamoto, M. Tada, A. Kakita, and Y. Ugawa. 2018. “Altered Expression of Glutamate Transporter-1 and Water Channel Protein Aquaporin-4 in Human Temporal Cortex with Alzheimer's Disease”. Neuropathology and Applied Neurobiology. Wiley. doi:10.1111/nan.12475.
- Rodriguez-Vieitez, Elena, Stephen F. Carter, Konstantinos Chiotis, Laure Saint-Aubert, Antoine Leuzy, Michael Schöll, Ove Almkvist, Anders Wall, Bengt Långström, and Agneta Nordberg. 2016. “Comparison of Early-phase 11c-deuterium-l-deprenyl and 11c-pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease”. Journal of Nuclear Medicine. Society of Nuclear Medicine. doi:10.2967/jnumed.115.168732.
- Arakawa, Ryosuke, Per Stenkrona, Akihiro Takano, Sangram Nag, Rafael S. Maior, and Christer Halldin. 2017. “Test-retest Reproducibility of [11c]-l-deprenyl-d2 Binding to MAO-B in the Human Brain”. EJNMMI Research. Springer Science and Business Media LLC. doi:10.1186/s13550-017-0301-4.
- David Wilson 2021. "First-in-human Evaluation of EAAT2 PET Tracer in Healthy and Alzheimer's Diseased Brain". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05374278.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments